The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: Results from the UK TTP Registry

British Journal of Haematology

Volumn 171, Issue 5, 2015, Pages 830-835

  Hassan, Sevda ^a   Westwood, John Paul ^b   Ellis, Debra ^b   Laing, Chris ^c   Mc Guckin, Siobhan ^b   Benjamin, Sylvia ^d   Scully, Marie ^b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

ADAMTS13; Haemolytic uraemic syndrome; Thrombotic microangiopathies; Thrombotic thrombocytopenic purpura

Indexed keywords

CREATININE; SHIGA TOXIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE REGISTRY; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED KINGDOM; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTER; THROMBOTIC MICROANGIOPATHIES; VERY ELDERLY; YOUNG ADULT;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHILD; CHILD, PRESCHOOL; CREATININE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REGISTRIES; RETROSPECTIVE STUDIES; THROMBOTIC MICROANGIOPATHIES; YOUNG ADULT;

EID: 84955401380     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13654     Document Type: Article

References (15)

1. Chow, K.V., Carroll, R., Branley, P., Nicholls, K., Becker, G. & Hogan, C. (2007) Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange. Internal Medicine Journal, 37, 329-332.
2. Coppo, P., Schwarzinger, M., Buffet, M., Wynckel, A., Clabault, K., Presne, C., Poullin, P., Malot, S., Vanhille, P., Azoulay, E., Galicier, L., Lemiale, V., Mira, J.P., Ridel, C., Rondeau, E., Pourrat, J., Girault, S., Bordessoule, D., Saheb, S., Ramakers, M., Hamidou, M., Vernant, J.P., Guidet, B., Wolf, M. & Veyradier, A. & French Reference Center for Thrombotic Microangiopathies. (2010) Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE, 5, e10208.
3. Fontana, S., Gerritsen, H.E., Kremer Hovinga, J., Furlan, M. & Lammle, B. (2001) Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. British Journal of Haematology, 113, 100-102.
4. Furlan, M., Robles, R., Solenthaler, M. & Lammle, B. (1998) Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood, 91, 2839-2846.
5. Kavanagh, D. & Goodship, T. (2010) Genetics and complement in atypical HUS. Pediatric Nephrology(Berlin, Germany), 25, 2431-2442.
6. Kokame, K., Nobe, Y., Kokubo, Y., Okayama, A. & Miyata, T. (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. British Journal of Haematology, 129, 93-100.
7. Loirat, C. & Fremeaux-Bacchi, V. (2011) Atypical hemolytic uremic syndrome. Orphanet journal of rare diseases, 6, 60.
8. NICE (2015) Eculizumab for Treating Atypical Haemolytic Uraemic Syndrome. NICE Highly Specialised Technology Guidance (HST1). National Institute for Health and Care Excellence, London. Available at: http://www.nice.org.uk/guidance/hst1.
9. Noel, N., Maigne, G., Tertian, G., Anguel, N., Monnet, X., Michot, J.M., Goujard, C. & Lambotte, O. (2013) Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency. QJM, 106, 1017-1022.
10. Scully, M. & Goodship, T. (2014) How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. British Journal of Haematology, 164, 759-766.
11. Scully, M., Cohen, H., Cavenagh, J., Benjamin, S., Starke, R., Killick, S., Mackie, I. & Machin, S.J. (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology, 136, 451-461.
12. Scully, M., Hunt, B.J., Benjamin, S., Liesner, R., Rose, P., Peyvandi, F., Cheung, B. & Machin, S.J. (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology, 158, 323-335.
13. Som, S., Deford, C.C., Kaiser, M.L., Terrell, D.R., Kremer Hovinga, J.A., Lammle, B., George, J.N. & Vesely, S.K. (2012) Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion, 52, 2525-2532; quiz 2524.
14. Tsai, H.M. & Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, 339, 1585-1594.
15. Zuber, J., Fakhouri, F., Roumenina, L.T., Loirat, C. & Fremeaux-Bacchi, V. (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Reviews Nephrology, 8, 643-657.